44 results about "Octreotide" patented technology

A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.

The present invention relates to an octreotide sustained release delivery system for treatment of diseases relating to somatotropin and/or somatostatin. The sustained release delivery system of the invention includes a flowable composition containing an octreotide compound, and an implant containing the octreotide compound. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and an octreotide compound.

The invention relates to the field of preparation of compounds, especially to a preparation method for octreotide. The preparation method comprises the following steps: subjecting dipeptide and a solid-phase synthetic hexapeptide resin to condensation so as to prepare linear octapeptide; dissolving linear octapeptide obtained after cracking in an aqueous solution of N,N-dimethyl formamide; and adding an oxidizing agent for cyclization and purification so as to prepare octreotide. The preparation method enables yield and purity of octreotide to be improved.

The invention relates to a preparation method of octreotide, which comprises the steps of preparing crude linear peptide by an Fmoc/tBu solid-phase peptide synthesis method and preparing octreotide from the crude linear peptide through oxidizing reaction, wherein the oxidizing reaction is carried out under the pH of 7.0-7.5 and in the presence of hydrogen peroxide, and the charging molar ratio of the hydrogen peroxide and the crude linear peptide is 7-9/1. The invention adopts the hydrogen peroxide to oxidize the crude linear peptide so as to obtain the octreotide, the oxidizing reaction can be finished only within 1-3h, compared with the traditional air oxidizing method, the reaction time is greatly shortened, the octreotide product yield is tremendously improved, and the method is suitable for mass production of the octreotide and salts thereof.

The invention relates to synthesis method for industrial production of octreotide. The method is characterized by comprising the following steps of: 1. taking aminomethyl resin as the starting resin, utilizing condensation reagents HOBT and DIC to couple the raw material Fmoc-Thr-x to the resin to generate Fmoc-Thr-x AM Resin; then coupling amino acids Cys, Thr, Lys, Trp, Phe, Cys and Phe to Fmoc-Thr-x AM Resin one by one in order, thus obtaining octreotide peptide resin; 2. adding a lysate solution, stirring the substances evenly and performing cracking for 2-3h; 3. dissolving octreotide crude peptide into a TFA/water mixed solution, then putting the mixture into 35DEG C-38DEG C water bath to perform heating for 2-3h to make the linear peptide of octreotide have single peak pattern in HP LC chromatogram; and 4. adding DMSO, then performing oxidation for 1-1.5h, conducting HPLC detection of a cyclization end point, and performing separation and purification to obtain a refined product of octreotide. In short, the synthesis method provided by the invention has simple technique, and is suitable for industrial production. After post-treatment, the HPLC peak pattern of octreotide crude peptide is simple, the cyclization method is easy to operate, cyclization is complete, the yield is high and the purity is 98% or more.

Microspheres for releasing an octreotide compound without an initial time lag include a poly(D,L-lactide-co-glycolide) polymer (PLGA polymer) matrix having a ratio of lactide to glycolide ranging from 80:20 to 90:10 mol %. The polymer has a molecular weight ranging from about 6000 to 16000. The octreotide compound is dispersed in the polymer matrix. The microspheres can be made by forming a dispersed phase by combining the above polymer, dichloromethane, the octreotide compound, methanol and acetic acid. A target loading of the octreotide compound in the dispersed phase ranges from 7 to 12% by weight. Polyvinyl alcohol is dissolved in water to form a continuous phase. The dispersed phase is mixed in the continuous phase to form a microsphere suspension. The dichloromethane, acetic acid, methanol and polyvinyl alcohol are removed from the microsphere suspension. Residual dichloromethane and methanol are removed from the microspheres by washing.

The subject matter of the present invention is a cyclic or linear tetra- or pentapeptide binding to somatostatin receptors. The compounds of the invention are characterised in that they contain the radical of an amino carboxylic acid bearing a five-membered ring in the peptide backbone which may optionally contain O, S, Se, N, or P. These compounds are easy to prepare and display increased stability against peptidases. The compounds of the present invention induce apoptosis of tumour cells and the use of said compounds for cancer therapy is described. In particular, the compounds are characterised in that they are active even against tumour cells displaying resistance against other somatostatin derivatives such as octreotide. In addition, the use of the compounds of the invention for tumour diagnosis by means of positron-emission tomography is described, as well as their use as agents against neurogenic inflammation.

The invention relates to the field of medical polymer auxiliary materials and medicines, in particular to polyethylene glycol modified phospholipids derivatives (I) which take octreotide as a targeting ligand. In the polyethylene glycol modified phospholipids derivatives (I), a polyethylene glycol long chain has the function of spatial stabilization and makes modified liposome realize long circulation; simultaneously, the octreotide is connected to the outside of a PEG hydrophilic chain, exposed to the outer layer of the liposome and not influenced by the PEG chain; and the conjugation between active targeting tumor cells and a cell membrane SSTR receptor is maintained after the liposome is effluent out of a tumor novel blood vessel, so as to improve uptake of liposome-containing medicines of tumor cells.

The invention provides a somatostatin precursor compound of octreotide, and belongs to the technical field of radioactive drugs and nuclear medicine.The precursor compound is NOTA-TATE, and the structure is shown in the following formula I (the formula is shown in the description). The invention also provides a somatostatin ligand compound of the octreotide, wherein the precursor compound NOTA-TATE is labeled by using radionuclide A to obtain A-NOTA-TATE.The invention also provides a method for preparing the somatostatin precursor compound and the somatostatin ligand compound of the octreotide.The ligand compound obtained by nuclide labeled NOTA-TATE is a colorless transparent liquid injection, has the advantages of simple preparation process, short time-consuming, high labeling rate, stable labeling, good affinity with somatostatin receptors, good targeting for tumor and good imaging effect,can be used for differential diagnosis, staging, accurate localization of focus, treatment andcurative effect monitoring of neuroendocrine tumors, and has good application prospects.

The invention relates to a sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers. In other words, the present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).

The invention discloses a drug for neuroendocrine tumors and a process thereof, and specifically relates to the field of biopharmaceuticals, wherein the drug includes the following raw materials: cysteamine hydrochloride, Boc2O, TPE-NHS, Boc-SS-NH2, HOOC-PEG5k-NH2, BLG-NCA, NHS, octreotide, 3-aminophenylboric acid and ETO. With phenylborate bonds contained in the drug, micelles can maintain structural stability in blood circulation, thereby protecting an encapsulated drug, reducing drug leakage, and reducing systemic toxic and side effects. When the drug-loaded micelles are gathered in tumor tissues through the EPR effect, octreotide on the surface of the micelles can specifically bind to the overexpressed somatostatin acceptors of neuroendocrine tumor cells, so as to enhance the targetingability of the micelles.

A Fe3O4/octreotide modified nano-liposome is an octreotide modified drug-loading nano-liposome with a particle size of 80-200 nm and with magnetic Fe3O4 nano particles on the surface. According to a preparing method of the Fe3O4/octreotide modified nano-liposome, a drug-loading liposome is modified with L-glutamic acid, so that the surface of the drug-loading liposome is negatively charged, and the surface of the nano-liposome is then modified with octreotide through electrostatic interaction; and Fe3O4 nano particles solution is mixed with the nano-liposome modified with octreotide based on a certain volume, and the Fe3O4/octreotide modified dual-target nano-liposome is prepared through interaction between PEG on the surface of Fe3O4 and the hydroxyl group on the surface of the lipidosome. The method is simple, operation is easy, the preparing condition is mild, the cost is low, adopted raw materials have no toxic or side effect on the human body, and the cancer treatment effect is improved by means of magnetic targeting, precise drug release and the specific binding capacity of octreotide to tumor cells.

The invention discloses an injection preparation before pancreas islet extraction by piglet pancreas. The injection preparation comprises octreotide and low molecular heparin sodium, the injection amount of octreotide is 1-3mum/kg; and the injection amount of low molecular heparin sodium is 5-15IU/kg. The operation is simple and easy to perform, pancreatin secretion can be greatly reduced, pancreas ischemic time is shortened, ischemic damage is reduced, pancreas islet loss is finally reduced, islet yield can be effectively increased, activity can be protected, the injection preparation provides available resource for preparing and transplanting provide, and has wide clinical application prospect.

The invention relates to the field of medicinal synthesis and discloses a method for synthesizing octreotide. According to the method disclosed by the invention, special Boc-Thr(Bzl)-OL-Merrifield serves as an initial resin, an iodine oxidation method, a trifluoroacetic acid solution acidolysis resin of hydrogen bromide, protecting groups and other manners are matched to realize all-solid-phase preparation of the octreotide. Finally, the prepared octreotide has high purity and total yield. Meanwhile, the preparation process is greatly simplified, the preparation time is shortened, and the production cost is reduced.

The invention discloses a preparation method for octreotide. The preparation method comprises the following step: successively subjecting a solution of a crude octreotide precursor product to reversed-phase cyclization, reversed-phase purification and reversed-phase desalination by adopting a highly-efficient liquid-phase reversed-phase chromatography process, wherein a filling material for the highly-efficient liquid-phase reversed-phase chromatography process is a styrene-divinyl benzene copolymer; and the crude octreotide precursor product contains two free sulfhydryl groups. The preparation method provided by the invention prepares a pure polypeptide product by adopting reversed-phase adsorption for cyclization, purification and desalination through a one-step method, optimizes production process, and is applicable to continuous industrial production.

This invention provides a method for causing weight loss in a subject comprising introducing biodegradable microspheres into one or more of the subject's gastric arteries, wherein the microspheres (i) have a d₉₀ value from 40 μm to 500 μm; (ii) comprise polylactic acid (PLA) and/or polylactic co-glycolic acid (PLGA); (iii) carry a therapeutically effective amount of pharmaceutical octreotide; (iv) embolize gastric arterial vessels supplied by the one or more arteries into which they are introduced; and (v) release octreotide during embolization.

The invention discloses octreotide sustained-release microspheres with high encapsulation rate and a preparation method thereof. The octreotide sustained-release microspheres are characterized in that the weight ratio of octreotide to polylactic-co-glycolic acid (PLGA) is 1:10-1:5; trehalose is used as a dispersion phase stabilizer, and the weight ratio of the trehalose to the octreotide is 1:10-1:1; polyvinyl alcohol and polysorbate 80 are continuous phase emulsifiers, the concentrations of the polyvinyl alcohol and the polysorbate 80 are respectively 5-30mg/ml and 0.1-0.6mg/ml, and the ratio of the polyvinyl alcohol to the polysorbate 80 is 50:1; and the pH value of a continuous phase is 7.0-9.0. The obtained octreotide microspheres are round, uniform in granularity distribution and high in encapsulation rate, the in-vitro medicament release performance accords with the characteristics of long-acting preparations, the medicament release percentage in 24 hours is less than 20 percent, and the accumulated release in 30 days reach over 80 percent.

The present invention relates to a medical composition for treatment, palliative care or prevention of cancer, such as medullary thyroid carcinoma. Specifically, the invention relates to a medical composition for treatment, palliative care or prevention of medullary thyroid carcinoma, which comprises liposomes modified with octreotide.

The invention discloses an octreotide composition based on subcutaneous gel slow release, a preparation method and application. The composition consists of the following ingredients in parts by weight: 20 to 50 parts of thermoplastic polymers, 50 to 70 parts of a biocompatible polar aprotic donor solvent and 2 to 15 parts of octreotide citrate. The octreotide composition prepared by the inventionis slowly degraded along with the slow degradation of a high molecular material after injection, and loaded medicine is slowly released into the body. The medicine release rate in the octreotide composition can be achieved by controlling the molecular weight of polymers and the loading amount of the medicine, so that the requirements of doctors and patients can be met in a targeted manner.